PMOS : Polyendocrine Metabolic Ovarian Syndrome — the new name for PCOS (May 2026)

What is PMOS?

PMOS — Polyendocrine Metabolic Ovarian Syndrome — is the new official name for what was previously known as PCOS (Polycystic Ovary Syndrome). The renaming was announced on May 12, 2026 in The Lancet, endorsed by a global consensus of 56 organizations including the Endocrine Society, the European Society of Human Reproduction and Embryology (ESHRE), and the World Health Organization (WHO).

Clinically, nothing has changed. PMOS remains the same hormonal and metabolic disorder that affects approximately 1 in 8 women of reproductive age worldwide — roughly 170 million people (Endocrine Society, 2026). Diagnostic criteria, treatments, and ICD-10 code E28.2 remain intact during the transition period (expected completion: ICD-11 update in 2028).

So why rename it? The three words of the new name each carry meaning. Polyendocrine acknowledges that multiple interacting hormonal systems are involved — not just the ovaries, but insulin signaling, the hypothalamic-pituitary axis, adrenal androgens, and thyroid function. Metabolic places insulin resistance and the associated cardiometabolic risks — type 2 diabetes, dyslipidemia, hypertension — at the center of the condition rather than treating them as side effects. Ovarian retains the ovarian dysfunction (irregular ovulation, follicular morphology) that remains a defining diagnostic feature (Endocrine Society 2026; WHO PCOS fact sheet 2024).

The word “polycystic” was dropped because it is factually inaccurate: the structures observed on ultrasound are not cysts — they are small antral follicles in arrested development. Calling them cysts has confused patients for decades and directed diagnostic attention away from the 20–30% of women with PMOS who have no ultrasound findings at all (“lean PMOS” phenotype). The French equivalent of this new name is SMOP — Syndrome Métabolique Ovarien Polyendocrinien. See our French-language guide on sopk-smop.fr/smop/.

This pillar page is the reference starting point for understanding PMOS in 2026. For the focused story of how the renaming happened, see our page on the PCOS → PMOS name change.

Why was PCOS renamed PMOS in 2026?

The push to rename PCOS did not begin in 2026 — it stretches back more than 14 years. The debate intensified after a landmark 2017 qualitative study by Gibson-Helm et al. documented how the word “cysts” caused severe confusion among patients: many believed they had ovarian tumors, others were told they did not have the condition because their ultrasound showed “no cysts.”

In 2021, the Endocrine Society and Monash University (Australia) surveyed 22,000+ respondents — patients, clinicians, and researchers — about the name. An overwhelming majority supported a change. Four core problems with “Polycystic Ovary Syndrome” emerged consistently:

1. “Polycystic” is factually wrong. The structures seen on pelvic ultrasound are antral follicles, not cysts. A true ovarian cyst is a fluid-filled sac; follicles are a normal part of the menstrual cycle. The misnomer has generated decades of diagnostic confusion.
2. “Ovarian” is too narrow. PMOS is a systemic, multi-organ condition involving insulin resistance, adrenal androgen overproduction, hypothalamic dysregulation, skin, hair, mental health, and long-term cardiovascular risk. Labeling it purely “ovarian” caused many doctors — and patients — to under-appreciate its metabolic severity.
3. Delayed diagnosis in lean women. Because of the emphasis on ultrasound findings and the assumption that PCOS = polycystic-appearing ovaries, the estimated 20–30% of women with PMOS who are lean or of normal weight faced average diagnostic delays of 2–3 years (ESHRE 2023). Lean phenotype PMOS is just as metabolically significant.
4. Stigmatization and fertility-focus. The old name anchored the condition in reproductive organs, which contributed to patients being told their condition “only matters if you want to get pregnant.” PMOS is a lifelong endocrine-metabolic condition with cardiovascular and psychological implications that extend well beyond fertility.

On May 12, 2026, The Lancet published the official international consensus announcing PMOS. A 3-year transition period was agreed upon: during this time, PCOS remains a recognized synonym, ICD-10 E28.2 is unchanged, and no patient needs to be re-diagnosed.

Sources: The Lancet 2026; Endocrine Society 2026; Gibson-Helm M et al., Fertil Steril 2017; Monash International PCOS Guideline 2023; ESHRE PCOS Guideline 2023.

Full deep-dive: The PCOS → PMOS rename: what really changes.

What is the difference between PCOS and PMOS?

Clinically, there is no difference. PMOS and PCOS refer to the exact same syndrome. The table below clarifies every dimension that patients and clinicians ask about:

The only substantive shift is conceptual: the new name frames the condition as primarily endocrine-metabolic rather than primarily ovarian-reproductive. This shift is expected to improve how clinicians screen for insulin resistance, cardiovascular risk, and mental health consequences — areas that have historically been under-managed (Endocrine Society 2026; ESHRE 2023).

What are the symptoms of PMOS?

PMOS symptoms span five interconnected domains. Because the condition is systemic, most women experience a combination — often without realizing they are related. The average time from first symptom to diagnosis remains 2–3 years (ESHRE 2023).

1. Menstrual cycle and ovulation

The most common presenting complaint is menstrual irregularity. Cycles shorter than 21 days or longer than 35 days, fewer than 8 cycles per year (oligomenorrhea), or complete absence of cycles (amenorrhea) are hallmark features. These reflect chronic oligo- or anovulation: the ovaries produce follicles that fail to fully mature and release an egg, which in turn disrupts normal progesterone and estrogen cycling. Over months and years, unopposed estrogen without the balancing effect of progesterone increases the risk of endometrial hyperplasia (×3 risk with chronic anovulation lasting over 6–12 months, ACOG 2018). Source: Monash International PCOS Guideline 2023.

2. Androgenic skin, hair, and scalp manifestations

Elevated androgens — testosterone, DHEAS, and androstenedione — drive several visible symptoms. Hormonal acne is typically located along the jaw, chin, neck, and upper back; it tends to be cystic and persistent, resistant to standard over-the-counter treatments. Hirsutism — excess dark, coarse hair growth in androgen-sensitive areas such as the upper lip, chin, chest, and inner thighs — is scored using the modified Ferriman-Gallwey scale (score ≥ 6 in Asian women, ≥ 8 in Caucasian women defines clinical hirsutism; ESHRE 2023). Female-pattern hair loss (androgenic alopecia) presents as diffuse thinning at the crown and widening of the central part, without frontal hairline recession. All three symptoms respond well to anti-androgenic treatments and are managed in our dedicated section below.

3. Metabolic and weight-related features

Insulin resistance affects 50–70% of women with PMOS regardless of body weight (Endocrine Society 2024). When cells resist insulin's signal, the pancreas compensates by producing more insulin (hyperinsulinemia). This excess insulin stimulates ovarian androgen production, creating a feedback loop that worsens hormonal imbalance. Symptoms include intense carbohydrate and sugar cravings, post-meal energy crashes, visceral fat accumulation (especially around the abdomen), and difficulty losing weight despite caloric restriction.

An important nuance: lean PMOS — affecting 20–30% of diagnosed women — involves the same insulin resistance and androgen excess, often without any significant weight gain. These women are frequently missed or dismissed because their presentation does not match the “classic” overweight profile (ESHRE 2023). Learn more about lean PCOS/PMOS. Metabolic syndrome — the cluster of central obesity, high triglycerides, low HDL, hypertension, and elevated fasting glucose — is present in 30–40% of obese women with PMOS (Cassar et al., 2024).

4. Mental health and cognitive impacts

The psychological burden of PMOS is substantial and systematically under-recognized. Women with PMOS have a 4× higher prevalence of anxiety and a 3× higher prevalence of depression compared to women without the condition (Barry et al., 2011 meta-analysis). This is driven by a combination of hormonal dysregulation (androgen excess, insulin resistance), the emotional impact of visible symptoms (acne, hair growth, weight), diagnostic delay and dismissal by healthcare providers, and chronic inflammation (elevated CRP and cytokines observed in PMOS; Escobar-Morreale 2018). Body image concerns are prevalent and significant (Barnard et al., 2007). Our tools on this site are built specifically to reduce the cognitive load of managing PMOS. Read our guide on PMOS and mental health.

5. Long-term cardiovascular and endocrine risks

PMOS is not a condition of reproductive years only. Women with PMOS carry a lifelong elevated risk of type 2 diabetes (×3 to ×7 vs. age-matched controls), dyslipidemia, hypertension, and non-alcoholic fatty liver disease (NAFLD — ×2 to ×3 risk; Lerchbaum et al., 2017). Cardiovascular risk increases meaningfully after menopause, with studies showing +20–40% excess risk in post-menopausal women with prior PMOS (Endocrine Society 2024; ACOG 2024). Annual metabolic screening — HbA1c, lipid panel, blood pressure — is recommended from the point of diagnosis throughout life.

How is PMOS diagnosed? (Rotterdam 2023 updated criteria)

PMOS is diagnosed when at least 2 of the following 3 Rotterdam criteria are present, after exclusion of other conditions that can mimic it:

Conditions that must be excluded before diagnosing PMOS:

• Late-onset congenital adrenal hyperplasia (CAH): elevated 17-hydroxyprogesterone (17-OHP), particularly in the morning (cortrosyn stimulation test if borderline).
• Thyroid dysfunction: TSH (hypo- or hyperthyroidism can mimic PMOS cycles and skin changes).
• Hyperprolactinemia: serum prolactin; a pituitary adenoma can suppress ovulation and elevate androgens.
• Cushing syndrome: 24-hour urinary free cortisol or overnight dexamethasone suppression test if clinical suspicion (central adiposity, striae, moon face).

Sources: Monash International PCOS Guideline 2023; ESHRE PCOS Guideline 2023. For a full breakdown of every blood test involved, see our lab tests guide.

The 4 PMOS phenotypes: A, B, C, D

Not all PMOS presentations are alike. The Rotterdam framework recognizes four clinical phenotypes based on which combination of the three diagnostic criteria is present. Phenotype determines metabolic risk level and informs treatment prioritization.

Phenotype A (all three criteria) carries the highest cardiometabolic risk, with significantly elevated HOMA-IR, triglycerides, and fasting insulin compared to phenotypes C and D. Phenotype D is the classic “lean PMOS” presentation — normal BMI, no hyperandrogenism, but still significant anovulation and ovarian morphology changes. Want to know your phenotype? Take our free 3-minute phenotype quiz.

What blood tests for PMOS? (printable checklist)

A thorough PMOS workup serves two purposes: confirming the diagnosis and establishing a metabolic baseline that guides long-term monitoring. The following checklist is based on Monash 2023 and ESHRE 2023 recommendations. Our lab tests guide explains each marker in plain language.

Sources: Monash International PCOS Guideline 2023; ESHRE PCOS Guideline 2023; Endocrine Society Position Statement 2024. Print-ready version with reference ranges: /pcos-lab-tests/.

PMOS treatments in 2026

PMOS management is individualized and depends on the patient's primary concerns (cycles, fertility, acne, weight, mental health) and phenotype. The following seven approaches represent current evidence-based options per Monash 2023, ESHRE 2023, and Endocrine Society 2026.

1. Lifestyle interventions (first-line for all phenotypes)

Lifestyle modification is the first-line treatment for all women with PMOS who are overweight or obese — and is recommended for lean women as well. The targets: a Mediterranean-pattern diet (anti-inflammatory, low glycemic load), at least 150 minutes per week of mixed aerobic and resistance exercise, and 7–9 hours of sleep per night (sleep restriction worsens insulin resistance and cortisol, further disrupting hormonal balance). The evidence is compelling: even a 5–10% reduction in body weight in overweight women with PMOS restores spontaneous ovulation in 55–75% of cases and significantly reduces androgen levels and fasting insulin (Kiddy et al., 1992; Hoeger et al., 2008; Monash 2023). These effects occur independently of the specific diet used, suggesting total caloric balance and insulin load matter most.

2. Myo-inositol (40:1 myo:D-chiro ratio)

Inositol — specifically the combination of myo-inositol and D-chiro-inositol at a 40:1 ratio — has the strongest evidence base among supplements for PMOS. A 2023 meta-analysis of 26 randomized controlled trials showed 69.8% menstrual cycle restoration with myo-inositol versus 62.6% with metformin, with significantly better tolerability (no GI side effects). Inositol improves insulin sensitivity, reduces free testosterone, and enhances oocyte quality in women pursuing assisted reproduction. Typical dose: 4 g myo-inositol + 400 mg D-chiro-inositol daily. Inositol vs metformin: full comparison.

3. Metformin (off-label insulin sensitizer)

Metformin is not FDA-approved for PMOS specifically but is widely used off-label. It is classified as Grade B recommendation in ESHRE 2023 — meaning it is recommended for metabolic management (insulin resistance, prevention of T2D, weight support) in women who do not tolerate lifestyle changes alone. Standard dose: 1500–2000 mg/day (extended-release preferred for GI tolerability). Metformin is not first-line for cycle regulation or fertility in the absence of insulin resistance. Full guide: Metformin and PMOS.

4. Combined oral contraceptives (COC) with anti-androgenic progestin

COCs are the first-line pharmacological treatment for acne, hirsutism, menstrual cycle regulation, and endometrial protection in women with PMOS who do not want pregnancy. Not all COCs are equivalent: progestins with anti-androgenic properties — drospirenone (e.g., Yasmin, Yaz) and dienogest — are preferred over levonorgestrel or norethindrone, which can paradoxically worsen androgen-related symptoms. COCs suppress LH-driven ovarian androgen production and increase SHBG, further reducing free testosterone. Full effect on acne and hirsutism typically requires 3–6 months. Birth control and PMOS: what to know.

5. Spironolactone (anti-androgen for skin, hair, acne)

Spironolactone — an aldosterone antagonist and androgen receptor blocker — is used at doses of 100–200 mg/day for hirsutism, hormonal acne, and female-pattern hair loss (FPHL) in PMOS. It is highly effective (60–80% reduction in hirsutism scores over 6 months) and is considered when COCs alone are insufficient. Mandatory: effective contraception during spironolactone use due to risk of feminization of a male fetus if pregnancy occurs. Monitoring: potassium levels, blood pressure (it is mildly diuretic). Spironolactone and PMOS: complete guide.

6. Letrozole (first-line for ovulation induction, fertility)

Since the publication of the landmark Legro et al. trial in the New England Journal of Medicine (2014) and the subsequent ESHRE/Monash 2023 guideline update, letrozole has replaced clomiphene citrate as the first-line treatment for ovulation induction in women with PMOS seeking pregnancy. The data is clear: letrozole achieves a 27.5% live birth rate vs 19.1% for clomiphene (Legro 2014, NEJM), with lower rates of multiple pregnancy. Letrozole is an aromatase inhibitor (originally developed for breast cancer) that temporarily suppresses estrogen, triggering compensatory FSH release and single dominant follicle development. Letrozole and PMOS: dosing, cycles, outcomes.

7. GLP-1 receptor agonists — semaglutide/tirzepatide (off-label)

The most significant development in PMOS pharmacotherapy in 2024 was the publication of the SURMOUNT-PCOS trial in the New England Journal of Medicine (2024). Tirzepatide (GLP-1/GIP dual agonist, brand name Mounjaro/Zepbound) produced:

• −20.2% average weight reduction at 72 weeks
• 80% menstrual cycle restoration in the tirzepatide group vs 29% in placebo
• Significant reductions in testosterone, HOMA-IR, and hirsutism scores

GLP-1 agonists remain off-label for PMOS specifically; access depends on insurance and country-level approval for obesity management. Not recommended during pregnancy or breastfeeding. Ozempic, Mounjaro, and PMOS: what the evidence says.

PMOS long-term complications

PMOS is a lifelong condition with systemic health consequences that extend well beyond the reproductive years. Understanding these risks is not meant to alarm — it is meant to motivate proactive monitoring that can prevent or significantly delay their onset.

The key takeaway: PMOS is manageable. Women who maintain active cardiometabolic monitoring and adopt lifestyle interventions early significantly reduce their lifetime risk for all of the above complications. Annual metabolic screening (HbA1c, lipids, blood pressure) from diagnosis is not optional — it is protective.

Living with PMOS day-to-day

Living with PMOS means navigating a condition that is common but often misunderstood — by healthcare providers and the broader public alike. The average diagnostic delay of 2–3 years (ESHRE 2023) is not just a statistic: it represents years of symptoms dismissed, cycles labeled “just stress,” acne blamed on diet alone, and weight gain attributed to lack of willpower. Many women receive a diagnosis only when they seek fertility treatment.

The emotional toll is real and documented. Women with PMOS report significantly higher rates of anxiety (×4 prevalence; Barry et al., 2011) and depression (×3 prevalence; Barry et al., 2011) than the general population. Body image disturbance is widespread and specifically linked to the androgenic symptoms — acne, hirsutism, weight — that are externally visible and socially loaded (Barnard et al., 2007). The intersection of invisible internal dysfunction (insulin resistance, irregular ovulation) with highly visible external symptoms creates a unique psychological burden.

Chronic fatigue — often dismissed as laziness — is driven by a combination of insulin dysregulation (post-meal crashes, reactive hypoglycemia), poor sleep quality (PMOS increases risk of obstructive sleep apnea, particularly in overweight phenotypes), and mood disturbances. Understanding these mechanisms can shift the framing from self-blame to physiological explanation.

This site exists to reduce that burden. Our tools are built to be practical, compassionate, and guilt-free. We don't recommend extreme diets. We don't imply you need to lose weight to deserve treatment. We do provide evidence-based information and structured tools so that you arrive at medical appointments informed and empowered.

Practical starting point: Build your PMOS appointment summary in 10 minutes — a printable PDF that organizes your symptoms, test results, and questions before you see your doctor.

Frequently asked questions about PMOS

The following questions are based on what patients most commonly ask after receiving a PMOS/PCOS diagnosis. Each answer reflects current evidence (Monash 2023, ESHRE 2023, Endocrine Society 2024–2026).

What is the difference between PCOS and PMOS?

No clinical difference. PMOS (Polyendocrine Metabolic Ovarian Syndrome) is simply the new official name for PCOS, adopted on May 12, 2026 by 56 international organizations including the Endocrine Society and The Lancet. Diagnostic criteria, treatments, and medical codes remain identical pending ICD-11 update expected in 2028.

Do I need to get re-diagnosed after the renaming?

No. If you already have a PCOS diagnosis, it remains valid. The renaming requires no additional medical steps. Your doctor can simply note "PMOS (formerly PCOS)" in your records.

My doctor doesn't know the new name — how do I bring it up?

You can show them our page on the renaming or reference The Lancet publication of May 12, 2026. The term PMOS is still being adopted across healthcare systems. Simply say: "PCOS was renamed PMOS in May 2026 by an international consensus of 56 organizations."

Is PMOS hereditary?

Yes, partially. The risk is 5 to 6 times higher if your mother or sister has it. Genes such as DENND1A, THADA, FSHR, and YAP1 have been identified (Endocrine Society 2024). But genetics is not the only factor — diet, lifestyle, and environment also play a role.

Can I get pregnant with PMOS?

Yes. Fertility is reduced but preserved in the vast majority of cases. With appropriate care, 70–80% of women with PMOS who want a pregnancy achieve one. Letrozole is the first-line treatment for ovulation induction since 2023 (ESHRE/Monash 2023), with a 27.5% live birth rate vs 19.1% for clomiphene (Legro 2014, NEJM).

Does PMOS disappear at menopause?

No. 80% of women with PMOS retain symptoms after age 50 (JCEM 2024). Menopause may reduce irregular cycles and sometimes acne, but worsens insulin resistance and cardiovascular risk. Adapted cardiometabolic monitoring remains necessary.

What HOMA-IR is normal in PMOS?

HOMA-IR thresholds vary by study. In practice: < 2.0 = no significant insulin resistance; 2.0–2.9 = watchfulness zone; ≥ 3.0 = probable insulin resistance. Some labs use 2.5 as the threshold. Our free HOMA-IR calculator gives you your result instantly.

Does inositol really work for PMOS?

Yes, with solid data. Myo-inositol (40:1 myo:D-chiro ratio) improves insulin resistance, restores cycles in 60–70% of women, and improves oocyte quality. A 2023 meta-analysis (26 RCTs) shows 69.8% cycle restoration vs 62.6% for metformin. Tolerability is far superior to metformin.